Background Prolonged storage improves availability of platelet products but could also influence safety and efficacy. This systematic review and metaanalyses summarize and quantify the evidence of the effect of storage time of transfused platelets on clinical outcomes.
Introduction
Platelets are transfused to prevent or treat bleeding complications in patients with thrombocytopenia or platelet dysfunction [1] . Platelet products can be stored for a maximum of 4-7 days, depending on national guidelines and type of product [2] [3] [4] [5] . During the period 2000-2002, a survey found the mean annual discard rate for 17 blood banks in 10 countries to be 13% (range 6Á7-25%). As outdating was the main reason for discarding platelet products, prolonging storage is likely to reduce the number of discarded units [6] . However, in vitro studies demonstrated a gradual loss of platelet function during storage at room temperature, which is known as the 'storage lesion' [7] .
We previously performed a systematic review and meta-analyses on the effect of storage time at room temperature on clinical measurements. In these meta-analyses, older platelets had inferior results on all end-points as compared to fresher products [8] . However, the clinical implications of these effects are not clear [9, 10] . Therefore, the aim of the current systematic review and metaanalyses was to quantify the effect of storage time of platelet products on clinical outcomes after transfusion.
Methods
The search strategy, study selection, methods for assessing the risk of bias and the data extraction were described previously and are in accordance with a prespecified study protocol [8] .
Search strategy
In brief, a systematic search was applied to seven databases: MEDLINE (PubMed), EMBASE, Cochrane, CINAHL, Academic Search Premier, ScienceDirect and Web of Science. Results were checked for missing relevant papers by experts in the field, and the search strategy was adapted as needed. The search was last updated and performed in February 2016. The search strategy contained synonyms for platelets, fresh, old and storage time. No limitations were placed on study design, language or year of publication (Table S1 ).
Study selection
As specified in the study protocol, two reviewers independently screened titles and abstracts for relevance. Inclusion criteria were as follows: performed in humans, concerning platelet transfusion, reporting clinical outcomes, reporting different storage times and reporting original data. Disagreements were discussed with a third reviewer. The risk of bias was scored according to the 'Cochrane Collaboration's tool for assessing risk of bias' for randomized controlled trials [11] and 'Fowkes & Fulton tool' for randomized controlled trials and observational studies [12] . The items in the Fowkes and Fulton tool are appropriate study design, representative study sample, acceptable control group, quality of measurements and outcome, completeness, confounding, which is similar as in the ACROBAT-NRSI Cochrane tool for assessing nonrandomized studies [13] . Papers scoring insufficient on one of these items were excluded.
Studies could only be included in the meta-analyses if they reported both a point estimate and a measure of precision. Further, studies needed to report an effect measure which could be recalculated to allow pooling with data from other studies (e.g. some studies reported only mean storage time in cases and controls, whereas risk ratios were reported in other studies). Papers written in other languages than English were translated, and data extraction was verified by native speakers.
Data extraction
Storage time, type of outcome, product type, point estimate and measure of precision were recorded. Authors of included studies were contacted when additional information was needed. If necessary, original results were recalculated in order to enable pooling of the results. In all cases where the underlying distribution could be assumed to be normal, mean and standard deviation were calculated from median, range and quartiles [14] . Results expressed in hours were recalculated to days.
Categorization
Storage time was dichotomized into fresh and old. Where storage time was already dichotomized, the reported dichotomization was maintained. Most papers defined fresh as ≤3 days and old as ≥4 days. Therefore, these definitions were used to summarize results if papers reported multiple storage time categories, using standard formulas for combining samples sizes (Σn i ), means (
) from multiple groups. Results were grouped by product: apheresis, pathogen-reduced apheresis (PR_aph), buffy coat in plasma (BC_plasma), buffy coat in platelet additive solution (BC_PAS), pathogen-reduced buffy coat in platelet additive solution (PR_BC PAS) and platelet-rich plasma (PRP). If papers reported results concerning different products, these were handled as separate results.
Outcomes
Papers reporting laboratory measurements (i.e. corrected count increments, count increment, platelet recovery, survival, half-life) were reported elsewhere [8] . Outcomes related to safety aspects were categorized into transfusion reactions, as defined by Delaney et al. [15] ; complications, including other adverse events; mortality; and length of hospital stay. In-hospital mortality for trauma patients was assumed to be equivalent to 60-day mortality, if no additional data were available. In other words, we assumed that it was very unlikely that trauma patients who were discharged alive subsequently died within 60 days. The cut-off point of 60 days was chosen, as these data were available in other papers reporting mortality.
Outcomes related to efficacy aspects were categorized into bleeding, transfusion interval, transfusion need (i.e. number of platelet, red blood cell and plasma transfusions, or amount of cryoprecipitate during hospital stay or period of 5 days, as reported), repeated transfusion within 24 h and haemostatic potential as measured by thromboelastography.
Statistical analyses
For studies reporting only incidences of transfusion reactions, complications, mortality and bleeding, the relative risk was calculated using standard formulas [16] . The corresponding 95% confidence intervals were calculated using Fisher's exact test. Standard errors were determined from the confidence intervals. For casecontrol studies, odds ratios were calculated with standard errors according to the formula of Woolf [17] . The included case-control studies selected controls in a way which allowed the reported odds ratios to be interpreted as relative risks [18] . These odds ratios were therefore treated as relative risks in all analyses. Relative risks reflecting the risk of stoppage of bleeding or improvement in bleeding rate were recalculated to reflect the risk of no stopping of bleeding or no improvement of bleeding rate.
For continuous outcomes, weighted mean differences (WMD) were calculated. If more than ten studies were included, a prespecified subgroup analysis was performed, based on product type (i.e. before or after implementation of universal leucoreduction). Metaregression was performed to examine the impact of product type on the pooled estimate. The adjusted R-squared (R ) was calculated to examine the proportion of heterogeneity explained by product type. A sensitivity analysis was performed, excluding the studies with the largest standard errors and meeting abstracts.
To assess the risk of publication bias, funnel plots were generated and Egger's bias coefficient was calculated [19] . A single funnel plot was made for all continuous endpoints combined. To standardize all outcomes to the same scale, the standardized mean difference (SMD) was calculated for each comparison. The standardized mean difference expresses the size of the intervention effect in each comparison relative to the standard deviation estimated in that comparison [20] . All studies were centred around the point of no effect by subtracting the pooled standardized mean difference for each outcome from the standardized mean difference for that outcome of each comparison.
Heterogeneity was quantified by the I² statistic, which ranges from 0-100% and calculates the proportion of variation due to heterogeneity rather than due to chance [21] . To account for substantial heterogeneity, a random-effects model was used for all meta-analyses. As a sensitivity analysis, we performed a meta-analysis including only the observational studies. All statistical analyses were performed using Stata version 14, packages metan and metareg.
Results

Selection
The literature search yielded 4234 papers, of which title and abstract were screened for the predefined inclusion criteria, as described previously [8] . Following selection on inclusion criteria and the risk of bias, 32 studies, reporting 59 unique comparisons, were included in this systematic review (Fig. 1 ). This included five meeting abstracts and 27 original papers. Four papers reported on trials in which storage time was randomized. Twentythree studies reported on observational cohort studies, of which five were secondary analyses on data of randomized trials. Five papers reported on case-control studies. Thirty-one papers were written in English and one in Chinese. Included studies are described in more detail in the online supplemental material.
Safety outcomes
Transfusion reactions
One randomized trial, two secondary analyses of randomized trials, nine cohort studies and five case-control studies reported transfusion reactions (Fig. 1 ). In ten papers, different kinds of transfusion reactions were reported as one combined end-point. In three papers, transfusion reactions were specified as febrile non-haemolytic transfusion reactions, in two papers as transfusion-related acute lung injury (TRALI), in one paper as allergic transfusion reaction and in one paper as septic transfusion reaction.
Twelve studies (thirteen comparisons) were included in the meta-analysis. The pooled risk ratio of old vs. fresh platelets was 1Á53 (95% confidence interval (CI) 1Á04-2Á25, I² 83Á1%) (Fig. 2) . Before universal leucoreduction was introduced, this risk ratio was 2Á05 (CI: 1Á47-2Á85, I 2 : 55Á6%) and after introduction, it was 1Á05 (CI: 0Á60-1Á84, I 2 : 80Á8%). The relative risk ratio of leucoreduced products compared to non-leucoreduced products was 0Á51 (CI: 0Á31-0Á86, I 2 : 68Á1%). Adjustment for leucoreduction explained 42Á36% of heterogeneity. Eggers bias coefficient was 1Á62 (P = 0Á26) (Supporting Information). Selection of the observational studies yielded a relative risk of 1Á05 (CI: 0Á57-1Á92) (Supporting Information). This was similar to the risk ratio in the randomized trial (RR: 1Á10, CI: 0Á22-5Á40). An additional analysis excluding the meeting abstracts and smaller studies gave similar results (Supporting Information). Five studies (six comparisons) were excluded from the meta-analysis, three were case-control studies comparing mean storage time in both groups, one study did not report the group sizes and one (two comparisons) only reported a regression coefficient. Of these six comparisons, two reported no difference in incidence of transfusion reactions between both storage time categories in leucoreduced products, three reported an increased incidence after exposure to older non-leucoreduced platelets and one reported no difference of mean storage time in cases and controls who received leucoreduced as well as non-leucoreduced products (Table 1) .
Other safety outcomes
Four cohort studies reported complications. Reported complications were as follows: major infection, defined as pneumonia, positive blood culture, leg wound infection, sternal wound infection or mediastinitis; positive blood culture; idiopathic pneumonia syndrome; and a composite end-point of sepsis, ARDS, renal failure or liver failure. Three studies, four comparisons, were included in the meta-analysis. The pooled risk ratio for these complications of old vs. fresh platelets was 1Á07 (CI: 0Á83; 1Á38, I² 66Á6%) (Fig. 2) . One paper could not be included in the meta-analysis, as it reported a hazard ratio of risk of idiopathic pneumonia syndrome, which was 0Á84 (CI: 0Á51-1Á37).
One randomized trial and two cohort studies reported mortality [22] [23] [24] . All were included in the meta-analysis. The pooled risk ratio for mortality was 1Á03 (CI: 0Á86-1Á24, I² 0Á0%) (Fig. 2) . The pooled risk ratio in observational studies was 1Á03 (CI: 0Á86-1Á25) compared to 0Á93 (CI: 0Á29-2Á96) in the randomized trial (Supporting Information).
Length of ICU stay was reported by one study, which found no difference for trauma patients receiving fresh or old platelets.
Efficacy outcomes
Transfusion interval
Three randomized trials, two secondary analyses of randomized trials and three cohort studies reported a transfusion interval. Four studies (five comparisons) were included in the meta-analysis. The interval between transfusions was 0Á25 days (CI: 0Á13-0Á38, I² 19Á5%) longer after transfusion of fresh platelets (Fig. 3) . The weighted mean difference in the observational studies was 0Á19 days (CI: 0Á14-0Á25), and in the two randomized trials, it was 0Á42 days (CI: 0Á10-0Á75) (Supporting Information). Four papers (five comparisons) were excluded from the pooled analysis, as these did not provide the necessary measure of precision. Three reported a longer interval following transfusion of fresh platelets. One paper reported no difference in interval following transfusion of apheresis platelet products and a shortened interval after transfusion of fresh pathogen-reduced products (Table 1) . Using the number of transfusions per study as weighing factor, the mean interval reported by the papers excluded from the meta-analysis was 0Á14 days.
Bleeding
Two randomized trials, two secondary analyses of randomized trials and two cohort studies papers reported data about bleeding. Reported bleeding end-points were as follows: incidence of any bleeding symptoms; incidence of bleeding in the central nervous system; percentage of transfusions resulting in lower WHO grade of bleeding; incidence of stopping of gastrointestinal bleeding, haemorrhagic cystitis or epistaxis; proportion of days with bleeding as measured by daily monitoring; and time from transfusion to first bleeding of WHO grade 2. In four studies, patients were assessed for bleeding symptoms daily. In two studies, medical records were reviewed for bleeding symptoms. Five studies (six comparisons) were included in the meta-analysis. The pooled risk ratio of old platelets vs. fresh platelets for any bleeding symptom was 1Á13 (CI: 0Á97-1Á32, I² 38Á4%). The pooled risk ratio in observational studies was 1Á18 (CI: 0Á99-1Á41), and in the two randomized trials, the pooled risk ratio was 0Á86 (CI: 0Á58-1Á27) (Supporting Information). Exclusion of the meeting abstracts gave similar results (Supporting Information). One paper could not be included in the pooled analysis, as it reported the time to first ≥WHO grade 2 bleeding (hazard ratio old vs. fresh: 1Á02 CI: 0Á62-1Á70). Studies can appear more than once if multiple products or multiple end-points were reported. Studies were excluded from the meta-analyses if no measure of precision was reported or if effect measure could not be recalculated in order to allow pooling of results. &Conclusion of the paper. 'No difference' means paper found no relevant differences between the groups. 
Transfusion need
One randomized trial and three cohort studies reported the need of transfusions. This was reported during hospital stay or during a period of 5 days. Three papers (three comparisons) were included in the meta-analysis on need of platelet transfusion. The weighted mean difference was 2Á76 fewer products (95% CI: -1Á11 to 6Á64, I² 84Á1%) with fresh platelets compared to old platelets (Fig. 3) . Two studies were performed among haematological patients and one among trauma patients. Selecting only studies in haematological patients yields a weighted mean difference of 4Á51 units (CI: 1Á92; 7Á11). The weighted mean difference in the two observational studies was 1Á66 units (CI: -2Á32 to 5Á64), and in the randomized trial, it was 6Á00 units (CI: 0Á90-11Á10) (Supporting Information). Four papers (four comparisons) were included in the meta-analysis on need of red blood cell transfusions. The weighted mean difference was 0Á08 products fewer (95% CI: -0Á18 to 0Á34, I² 3Á2%) after transfusion of fresh platelets. The weighted mean difference in the observational studies was 0Á07 units (CI: -0Á06 to 0Á25), and this was 2Á50 units (CI: -1Á23 to 6Á23) in the randomized trial (Supporting Information). Two papers (two comparisons) were included in the meta-analysis of need of plasma transfusions. The weighted mean difference was 0Á09 products fewer (95% CI: -0Á06 to 0Á25, I² 0Á0%) after transfusion of fresh platelets (Fig. 3) . One study reported the need of cryoprecipitate, which was not different after transfusion of fresh or old platelets (Table 1) .
Other efficacy outcomes
One randomized trial and one cohort study reported an increased risk of a repeated transfusion within 24 h (Table 1) . Results from these studies could not be pooled as the storage time of the old platelets in one paper coincided with the storage time of the fresh platelets in the other.
One study determined the haemostatic potential of platelets using thromboelastography (TEG) and reported better haemostatic properties of fresh platelets compared to old platelets (Table 1) .
Discussion
To conclude, transfusion of older platelet products was associated with more transfusion reactions before the implementation of universal leucoreduction. This association disappeared after the implementation of universal prestorage leucoreduction. Transfusion of older platelet products was associated with a shorter time to the next transfusion, a trend towards a higher risk of bleeding, and in haematological patients, an increased need of platelet transfusions. Storage time of platelet concentrates was not associated with the risk of mortality or the consumption of other blood products.
The association between storage time and laboratory measurements (i.e. platelet counts and derivatives thereof) has been reported elsewhere. That study reported inferior results for older platelets for all relevant measurements [8] . The current results suggest that these lower laboratory values are associated with a higher risk of bleeding and a shorter time to the next transfusion. Decreased efficacy of old platelets could explain the increased bleeding risk. Another explanation could be that platelet count is routinely measured on fixed moments, for example three times a week. Transfusion of older platelets results in lower increments, leading to a lower platelet count on average in case of a prophylactic transfusion strategy. This could result in an increased bleeding risk.
The increased risk of transfusion reactions in old platelets could be attributed completely to studies performed before the implementation of prestorage leucoreduction. Leucocytes and leucocyte-derived cytokines are thought to be a major cause of febrile non-haemolytic transfusion reactions [25, 26] .
With the implementation of universal leucoreduction, an absolute risk reduction of 25Á1% was expected in the risk of febrile non-haemolytic transfusion reactions [27] . The results of the present meta-analyses confirm the beneficial effect of prestorage leucoreduction on the incidence of transfusion reactions.
An important strength of these meta-analyses is that we were able to pool the available data on bleeding risk. Most studies are powered to study other outcomes and are therefore by themselves inconclusive on bleeding risk. Although different definitions of bleeding are used, we assume storage time has the same effect on all symptoms and it is appropriate to pool the estimates.
Another strength of this study is the broad search strategy. No limits were used for study design, year or language. Therefore, a maximum of available papers reporting clinical effects of storage time have been retrieved and all reported clinical outcomes were studied.
The broad search strategy also returned meeting abstracts, which are possibly more prone to bias. Exclusion of the meeting abstracts did not change the results of the main analyses, indicating these abstracts estimate the same effect. Due to the limited number of randomized trials, it was not feasible to perform a sensitivity analysis including only randomized trials. However, the pooled estimates of the observational studies were comparable with the results of the randomized trials. This suggests that the observational studies are reliable, allowing inclusion in the meta-analysis. The relatively large difference between the estimates of the observational studies and the randomized trials in transfusion interval is based on one precise observational study in which the difference in interval was 0Á19 days (CI: 0Á13-0Á24).
The main limitation of this study is that storage time had to be dichotomized into two broadly defined categories, fresh and old. Most studies reported differences between two groups and defined fresh as storage time of ≤3 days. Therefore, it was impossible to compare the safety and efficacy of platelets stored for 1-5 days with platelets stored for 6-7 days. Whereas, this is the difference between storage duration used in the Netherlands, compared with other countries [2] [3] [4] [5] .
Not all retrieved studies could be included in the metaanalyses, which could potentially induce selection bias. However, the studies excluded from the meta-analysis, regarding transfusion interval, reported on average a similar interval as the pooled estimate of the meta-analysis. For the outcomes of transfusion reactions and bleeding, the results of the excluded studies pointed in the same direction.
Another limitation of this study is the large heterogeneity between studies reporting transfusion reactions (I² 83Á1%). This is partly due to the difference in effect observed before and after the implementation of universal leucoreduction. Correction for leucoreduction in metaregression explained 42% of this heterogeneity. Other sources of variation could include the lack of standardized definitions and differences between active and passive monitoring of transfusion reactions. Among studies reporting bleeding symptoms, heterogeneity was moderate. This could be due to the fact that several different definitions of bleeding are used and it is measured in different ways. The number of studies reporting on the other outcomes was smaller, and therefore, it is difficult to detect heterogeneity and publication bias for these outcomes.
In conclusion, the safety and efficacy of platelet products deteriorate during storage. However, leucoreduction reduces the risk of transfusion reactions following transfusion of old platelets effectively. Efficacy of platelet transfusions is reduced after prolonged storage, leading to a shorter interval to the next platelet transfusion. Transfusion of old platelet concentrates might increase the risk of bleeding.
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